Study Title
A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy.
Purpose
To determine the effectiveness as well as safety & tolerability of AG013 in altering the onset, course & severity of oral mucositis compared to placebo (a mouth rinse which looks exactly the same as AG013 but which dose not contain AG013) when administered 3 times each day.
Eligibility
Study Process
Trial Details
Investigator:
IRB:
Advarra Institutional Review Board
IRB Number:
Trial Type:
NA
Sponsor:
Oragenics
Contact Information:
Radiation Oncology Services